{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 30,
        "end": 38
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 97,
        "end": 100
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 142,
        "end": 145
      }
    },
    {
      "id": "T8",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 184,
        "end": 187
      }
    },
    {
      "id": "T10",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 206,
        "end": 212
      }
    },
    {
      "id": "T14",
      "obj": "Disease",
      "span": {
        "begin": 227,
        "end": 242
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "24638003_10",
  "text": "When comparing the two arms , imatinib therapy was associated with higher RFS in patients with a KIT exon 11 deletion of any type , but not a KIT exon 11 insertion or point mutation , KIT exon 9 mutation , PDGFRA mutation , or wild-type tumor , although some of these patient groups were small ."
}
